Lantheus Holdings Inc (NASDAQ:LNTH) CEO Mary Anne Heino sold 25,538 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $21.21, for a total transaction of $541,660.98. Following the completion of the sale, the chief executive officer now owns 597,884 shares in the company, valued at $12,681,119.64. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Mary Anne Heino also recently made the following trade(s):
- On Thursday, June 20th, Mary Anne Heino sold 14,340 shares of Lantheus stock. The stock was sold at an average price of $27.89, for a total transaction of $399,942.60.
Shares of LNTH stock traded up $0.86 during trading hours on Friday, reaching $22.68. 7,351 shares of the stock traded hands, compared to its average volume of 287,048. Lantheus Holdings Inc has a 1-year low of $12.59 and a 1-year high of $29.80. The business has a fifty day moving average price of $23.28 and a 200 day moving average price of $24.68. The company has a quick ratio of 2.01, a current ratio of 2.62 and a debt-to-equity ratio of 2.05. The firm has a market capitalization of $829.20 million, a PE ratio of 24.01, a PEG ratio of 1.78 and a beta of 1.50.
Several hedge funds have recently added to or reduced their stakes in LNTH. Hancock Whitney Corp raised its stake in shares of Lantheus by 238.6% in the 2nd quarter. Hancock Whitney Corp now owns 31,798 shares of the medical equipment provider’s stock valued at $900,000 after buying an additional 22,408 shares in the last quarter. Mackenzie Financial Corp acquired a new position in shares of Lantheus in the 2nd quarter valued at $361,000. United Services Automobile Association acquired a new position in shares of Lantheus in the 2nd quarter valued at $235,000. Nuveen Asset Management LLC acquired a new position in shares of Lantheus in the 2nd quarter valued at $28,209,000. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Lantheus by 21.3% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,225,763 shares of the medical equipment provider’s stock valued at $62,989,000 after buying an additional 390,644 shares in the last quarter. Institutional investors and hedge funds own 94.36% of the company’s stock.
A number of research firms have recently issued reports on LNTH. Zacks Investment Research lowered shares of Lantheus from a “hold” rating to a “sell” rating in a report on Friday, August 2nd. BidaskClub lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Wednesday. ValuEngine lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, CJS Securities upgraded shares of Lantheus from a “market perform” rating to an “outperform” rating in a report on Friday, August 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $29.00.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Further Reading: Technical Analysis of Stocks, How Can It Help
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.